Phase 1/2 trial of BMS‐275291 in patients with human immunodeficiency virus‐related Kaposi sarcoma
Brett T. Brinker(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Jamie H. Von Roenn(American Society of Clinical Oncology), Jeannette Y. Lee(University of Arkansas at Little Rock), Lawrence D. Kaplan(UCSF Helen Diller Family Comprehensive Cancer Center), Amy Chadburn(Cornell University), Ethel Cesarman(Cornell University), David H. Henry(Pennsylvania Hospital), Susan E. Krown(Memorial Sloan Kettering Cancer Center)
Cited by 15
Related Papers
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588